Form 4: Enliven Therapeutics COO Anish Patel Executes Option Exercise and Stock Sale Under 10b5-1 Plan

Anish Patel, COO of Enliven Therapeutics, executed an option exercise and subsequent sale of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Anish Patel, the Chief Operating Officer of Enliven Therapeutics, Inc. [ELVN], reported changes in beneficial ownership of the company's stock.
• On May 9, 2024, Patel exercised an employee stock option to acquire 260 shares of common stock at a price of $2.48 per share.
• Simultaneously, Patel sold 260 shares of common stock at a weighted average price of $25.0596 per share, with individual sales ranging from $25.00 to $25.155.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on June 29, 2023.
• Following these transactions, Patel directly owns no shares of common stock and indirectly owns 394,027 shares through The Patel / Dong Family Trust Dated August 24 2017, for which he serves as trustee.
• Patel also directly owns 55,582 employee stock options.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document simply reports stock transactions by an executive under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment towards the company's prospects.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.

Future Outlook

There is no future outlook provided in this document.

Industry Context

This is a routine disclosure of stock transactions by a company executive, which is common in the pharmaceutical industry. These transactions are often part of pre-planned strategies for managing personal finances and do not necessarily reflect a change in the executive's confidence in the company.

Comparison to Industry Standards

• Executive stock transactions are a common occurrence in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• Companies like Amgen, Gilead Sciences, and Biogen regularly see similar filings from their executives.
• The use of 10b5-1 trading plans is a standard practice to ensure compliance with insider trading regulations.
• The size and frequency of these transactions are generally in line with industry norms for executives at similar levels.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the small number of shares involved.
• The transactions are unlikely to significantly affect employees, customers, suppliers, or creditors.

Key Dates